Cargando…
Molecular testing for adult type Alport syndrome
BACKGROUND: Alport syndrome (AS) is a progressive renal disease with cochlear and ocular involvement. The majority of AS cases are X-linked (XLAS) and due to mutations in the COL4A5 gene. Although the disease may appear early in life and progress to end stage renal disease (ESRD) in young adults, in...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780398/ https://www.ncbi.nlm.nih.gov/pubmed/19919694 http://dx.doi.org/10.1186/1471-2369-10-38 |
_version_ | 1782174479399518208 |
---|---|
author | Pont-Kingdon, Genevieve Sumner, Kelli Gedge, Friederike Miller, Chris Denison, Joyce Gregory, Martin Lyon, Elaine |
author_facet | Pont-Kingdon, Genevieve Sumner, Kelli Gedge, Friederike Miller, Chris Denison, Joyce Gregory, Martin Lyon, Elaine |
author_sort | Pont-Kingdon, Genevieve |
collection | PubMed |
description | BACKGROUND: Alport syndrome (AS) is a progressive renal disease with cochlear and ocular involvement. The majority of AS cases are X-linked (XLAS) and due to mutations in the COL4A5 gene. Although the disease may appear early in life and progress to end stage renal disease (ESRD) in young adults, in other families ESRD occurs in middle age. Few of the more than four hundred mutations described in COL4A5 are associated with adult type XLAS, but the families may be very large. METHODS: We classified adult type AS mutation by prevalence in the US and we developed a molecular assay using a set of hybridization probes that identify the three most common adult type XLAS mutations; C1564S, L1649R, and R1677Q. RESULTS: The test was validated on samples previously determined to contain one or none of these mutations. In the US, the test's clinical specificity and sensitivity are estimated to be higher than 99% and 75% respectively. Analytical specificity and sensitivity are above 99%. CONCLUSION: This test may be useful for presymptomatic and carrier testing in families with one of the mutations and in the diagnosis of unexplained hematuria or chronic kidney disease. |
format | Text |
id | pubmed-2780398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27803982009-11-21 Molecular testing for adult type Alport syndrome Pont-Kingdon, Genevieve Sumner, Kelli Gedge, Friederike Miller, Chris Denison, Joyce Gregory, Martin Lyon, Elaine BMC Nephrol Technical Advance BACKGROUND: Alport syndrome (AS) is a progressive renal disease with cochlear and ocular involvement. The majority of AS cases are X-linked (XLAS) and due to mutations in the COL4A5 gene. Although the disease may appear early in life and progress to end stage renal disease (ESRD) in young adults, in other families ESRD occurs in middle age. Few of the more than four hundred mutations described in COL4A5 are associated with adult type XLAS, but the families may be very large. METHODS: We classified adult type AS mutation by prevalence in the US and we developed a molecular assay using a set of hybridization probes that identify the three most common adult type XLAS mutations; C1564S, L1649R, and R1677Q. RESULTS: The test was validated on samples previously determined to contain one or none of these mutations. In the US, the test's clinical specificity and sensitivity are estimated to be higher than 99% and 75% respectively. Analytical specificity and sensitivity are above 99%. CONCLUSION: This test may be useful for presymptomatic and carrier testing in families with one of the mutations and in the diagnosis of unexplained hematuria or chronic kidney disease. BioMed Central 2009-11-17 /pmc/articles/PMC2780398/ /pubmed/19919694 http://dx.doi.org/10.1186/1471-2369-10-38 Text en Copyright ©2009 Pont-Kingdon et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Technical Advance Pont-Kingdon, Genevieve Sumner, Kelli Gedge, Friederike Miller, Chris Denison, Joyce Gregory, Martin Lyon, Elaine Molecular testing for adult type Alport syndrome |
title | Molecular testing for adult type Alport syndrome |
title_full | Molecular testing for adult type Alport syndrome |
title_fullStr | Molecular testing for adult type Alport syndrome |
title_full_unstemmed | Molecular testing for adult type Alport syndrome |
title_short | Molecular testing for adult type Alport syndrome |
title_sort | molecular testing for adult type alport syndrome |
topic | Technical Advance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780398/ https://www.ncbi.nlm.nih.gov/pubmed/19919694 http://dx.doi.org/10.1186/1471-2369-10-38 |
work_keys_str_mv | AT pontkingdongenevieve moleculartestingforadulttypealportsyndrome AT sumnerkelli moleculartestingforadulttypealportsyndrome AT gedgefriederike moleculartestingforadulttypealportsyndrome AT millerchris moleculartestingforadulttypealportsyndrome AT denisonjoyce moleculartestingforadulttypealportsyndrome AT gregorymartin moleculartestingforadulttypealportsyndrome AT lyonelaine moleculartestingforadulttypealportsyndrome |